NAD+ vs TB-500
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
NAD+
Nicotinamide Adenine Dinucleotide (NAD+) is an essential coenzyme found in every living cell. It plays a central role in energy metabolism, DNA repair, gene expression, and cellular signaling. NAD+ levels naturally decline with age, and restoring them has become a major focus of longevity research. Injectable NAD+ bypasses the GI tract for higher bioavailability compared to oral precursors like NMN or NR.
Full details →TB-500
Thymosin Beta-4 (TB-500) is a naturally occurring peptide present in almost all human and animal cells. It plays a crucial role in tissue repair and regeneration.
Full details →Side-by-Side Comparison
| Aspect | NAD+ | TB-500 |
|---|---|---|
| Dose Range | 20 mg–120 mg | 2 mg–2.5 mg |
| Frequency | Less than daily | Less than daily |
| Cycle Length | 4–12 weeks | 4–8 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | NAD+ is a critical substrate for sirtuins (SIRT1-7), a family of enzymes involved in DNA repair, inflammation regulation, and mitochondrial function. It also serves as a coenzyme for PARP enzymes (involved in DNA damage repair) and CD38 (involved in immune cell signaling). By directly replenishing cellular NAD+ pools, injectable NAD+ supports mitochondrial electron transport chain function, enhances ATP production, and activates longevity-associated pathways. | TB-500 promotes cell migration and differentiation, regulates actin (a cell-building protein), and reduces inflammation. It supports the formation of new blood vessels and wound healing. |
| Typical Dosage | Subcutaneous injection, typically 2–3 times per week. Start low and escalate: Twice per week protocol: Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 120 mg maintenance (0.6 ml). Three times per week protocol (e.g. Mon/Wed/Fri): Week 1: 20 mg (0.1 ml), Week 2: 40 mg (0.2 ml), Week 3+: 80 mg maintenance (0.4 ml). Volumes above assume 200 mg/ml concentration (100 mg vial reconstituted with 0.5 ml BAC water). Inject slowly — rapid administration increases flushing and nausea. Avoid back-to-back injection days. IV infusion (clinical setting): 250–750 mg per session over 2–4 hours. | Research protocols typically use 2-2.5mg twice weekly during the loading phase, followed by maintenance dosing of 2mg every 2 weeks. |
| Administration | Subcutaneous injection is the most practical route for self-administration. Inject slowly — rapid administration increases side effects (flushing, chest tightness, nausea). Some users split larger doses across multiple daily injections to improve tolerance. IV infusions provide the highest bioavailability but require a clinical setting. Store reconstituted NAD+ refrigerated and protect from light. NAD+ solutions are pH-sensitive; use bacteriostatic water for reconstitution. | Administered via subcutaneous or intramuscular injection. Some protocols suggest injection near injury sites. |
| Side Effects | Flushing and warmth (very common, especially at higher doses or fast injection rates). Nausea and mild GI discomfort. Chest tightness or pressure during injection (usually transient). Injection site pain or redness. Headache. These side effects are typically dose-dependent and diminish with slower administration and repeated use. | May cause temporary fatigue, headache, or localized irritation at injection sites. |
| Best For |
What They Have in Common
NAD+, TB-500 are both commonly used for:
Key Differences
Unique to NAD+:
Unique to TB-500:
Which Has Stronger Evidence?
- Recovery & Healing: TB-500 has stronger research support.
| Goal | NAD+ | TB-500 |
|---|---|---|
| Recovery & Healing | medium | high |
Key Studies
NAD+
- NAD(+) precursor supplementation in human ageing: clinical evidence and challenges.
Nature metabolism, 2025
- NAD(+) metabolism: pathophysiologic mechanisms and therapeutic potential.
Signal transduction and targeted therapy, 2020
- NAD(+) Intermediates: The Biology and Therapeutic Potential of NMN and NR.
Cell metabolism, 2018
TB-500
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.
Joint diseases and related surgery, 2026
- Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2024
- Adsorption effects of the doping relevant peptides Insulin Lispro, Synachten, TB-500 and GHRP 5.
Analytical biochemistry, 2017
Ready to Learn More?
Looking for trusted sources?